October 22, 2006 -- Biotech booked a gain for the fourth week in a row. The Centient Biotech 200™ climbed a solid 31 points to 3962, a rise of .80%, making the index positive for 2006. Breadth continues to be very strong in biotech stocks. The IPO world remains active, with three companies scheduled to price in the next week. Intermune was the leading percentage gainer for the week on the strength of its deal with Roche; StemCells gained without releasing any company news; Icos was up after receiving a buyout offer from Lilly; and Arena continued to climb on a recommendation from Jim Cramer. Amgen is scheduled to report after the bell on Monday. More details...
